人工合成长链多聚磷酸盐对凝血和血小板聚集的影响
|
摘要
目的:探讨人工合成长链多聚磷酸盐对凝血和血小板聚集的影响。方法:通过凝血常规检测、凝血因子活力检测和血小板聚集实验,检测人工合成长链多聚磷酸盐对凝血和血小板聚集的影响,采用ELISA、流式细胞术、高内涵成像技术探讨长链多聚磷酸钠盐的作用机制。结果:长链多聚磷酸盐可延长活化部分凝血活酶时间,降低凝血因子FⅧ、FⅨ、FⅪ、FⅫ活力,阻滞ADP诱导的血小板聚集,降低血小板内钙离子及TXA2浓度。结论:人工合成长链多聚磷酸盐可抑制内源性凝血并抑制血小板聚集,其机制可能与抑制血小板内钙离子及TXA2有关。
Objective: To investigate the effects of synthetic long-chain polyphosphate on blood coagulation and platelet aggregation. Methods: The effect of artificial synthetic long chain poly phosphate on blood coagulation and platelet aggregation was detected by coagulation tests, coagulation factor activity detection and platelet aggregation test,and its mechanism was explored by ELISA, flow cytometry and high content imaging system. Results: The long chain polyphosphates prolonged activated partial thromboplastin time,decreased coagulation factor FⅧ,FⅨ, FⅪ and FⅫactivity, blocked ADP-induced platelet aggregation, and decreased the concentration of calcium and TXA2 in platelet.Conclusion: The synthetic long-chain polyphosphate can inhibit endogenous coagulation and inhibit platelet aggregation,which may be related with the inhibition of intracellular calcium and TXA2.
Objective: To investigate the effects of synthetic long-chain polyphosphate on blood coagulation and platelet aggregation. Methods: The effect of artificial synthetic long chain poly phosphate on blood coagulation and platelet aggregation was detected by coagulation tests, coagulation factor activity detection and platelet aggregation test,and its mechanism was explored by ELISA, flow cytometry and high content imaging system. Results: The long chain polyphosphates prolonged activated partial thromboplastin time,decreased coagulation factor FⅧ,FⅨ, FⅪ and FⅫactivity, blocked ADP-induced platelet aggregation, and decreased the concentration of calcium and TXA2 in platelet.Conclusion: The synthetic long-chain polyphosphate can inhibit endogenous coagulation and inhibit platelet aggregation,which may be related with the inhibition of intracellular calcium and TXA2.
引文
1 Muller F,Mutch NJ,Schenk WA,et al.Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.Cell,2009,139(6):1143-1156.
2 Gajsiewicz JM,Smith SA,Morrissey JH.Polyphosphate and RNA Differentially Modulate the Contact Pathway of Blood Clotting.2017,292(5):1808-1814.
3 Faxalv L,Boknas N,Strom JO,et al.Putting polyphosphates to the test:evidence against platelet-induced activation of factorⅫ.Blood,2013;122(23):3818-3824.
4 Smith SA,Choi SH,Davis-Harrison R,et al.Polyphosphate exerts differential effects on blood clotting,depending on polymer size.Blood,2010;116(20):4353-4359.
5王新华,邸彦辉.熟蒜黄汁抗血小板聚集功能机制研究.中国实验血液学杂志.2014,22(3):753-757.
6 do Ceu Monteiro M,Sansonetty F,Goncalves MJ,et al.Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41.Cytometry,1999;35(4):302-310.
7 Walsh TG,Harper MT,Poole AW.SDF-lalpha is a novel autocrine activator of platelets operating through its receptor CXCR4.Cell Signal,2015;27(1):37-46.
8 Wada H,Matsumoto T,Yamashita Y.Diagnosis and treatment of disseminated intravascular coagulation(DIG)according to four DIC guidelines.J Intensive Care,2014;2(1):15.
9 Sangkuhl K,Shuldiner AR,Klein TE,et al.Platelet aggregation pathway.Pharmacogenet Genomics,2011;21(8):516-521.
10 Losol P,Palikhe NS,Lee JW,et al.Association of P2RY12polymorphisms with eosinophil and platelet activation in patients with aspirin-exacerbated respiratory disease.Ann Allergy Asthma Immunol,2015;114(5):423-424.
11 Jacobson KA,Paoletta S,Katritch V,et al.Nucleotides acting at P2Y receptors:connecting structure and function.Mol Pharmacol,2015;88(2):220-230.
12 Khanna V,Armstrong PC,Warner TD,et al.Prostaglandin E1potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro:Insights using short thromboelastography.Platelets,2015;26(7):689-692.
13 West LE,Steiner T,Judge HM,et al.Vessel wall,not platelet,P2Y12 potentiates early atherogenesis.Cardiovasc Res,2014;102(3):429-435.
14 Lordkipanidze M,Pharand C,Schampaert E,et al.A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.Eur Heart J,2007;28(14):1702-1708.
15 Khaspekova SG,Ziuriaev IT,Iakushkin VV,et al.Mean platelet volume:interactions with platelet aggregation activity and glycoproteinⅡb-Ⅲa andⅠb expression levels.Biomed Khim,2014;60(1):94-108.
16 Momeni A,Filiaggi MJ.Degradation and hemostatic properties of polyphosphate coacervates.Acta Biomater,2016;41:328-341.
17 Matczak J,Nowak P.The role of polyphosphates in the blood coagulation process and the inflammation progress.Wiad Lek,2016;69(6):818-824.
2 Gajsiewicz JM,Smith SA,Morrissey JH.Polyphosphate and RNA Differentially Modulate the Contact Pathway of Blood Clotting.2017,292(5):1808-1814.
3 Faxalv L,Boknas N,Strom JO,et al.Putting polyphosphates to the test:evidence against platelet-induced activation of factorⅫ.Blood,2013;122(23):3818-3824.
4 Smith SA,Choi SH,Davis-Harrison R,et al.Polyphosphate exerts differential effects on blood clotting,depending on polymer size.Blood,2010;116(20):4353-4359.
5王新华,邸彦辉.熟蒜黄汁抗血小板聚集功能机制研究.中国实验血液学杂志.2014,22(3):753-757.
6 do Ceu Monteiro M,Sansonetty F,Goncalves MJ,et al.Flow cytometric kinetic assay of calcium mobilization in whole blood platelets using Fluo-3 and CD41.Cytometry,1999;35(4):302-310.
7 Walsh TG,Harper MT,Poole AW.SDF-lalpha is a novel autocrine activator of platelets operating through its receptor CXCR4.Cell Signal,2015;27(1):37-46.
8 Wada H,Matsumoto T,Yamashita Y.Diagnosis and treatment of disseminated intravascular coagulation(DIG)according to four DIC guidelines.J Intensive Care,2014;2(1):15.
9 Sangkuhl K,Shuldiner AR,Klein TE,et al.Platelet aggregation pathway.Pharmacogenet Genomics,2011;21(8):516-521.
10 Losol P,Palikhe NS,Lee JW,et al.Association of P2RY12polymorphisms with eosinophil and platelet activation in patients with aspirin-exacerbated respiratory disease.Ann Allergy Asthma Immunol,2015;114(5):423-424.
11 Jacobson KA,Paoletta S,Katritch V,et al.Nucleotides acting at P2Y receptors:connecting structure and function.Mol Pharmacol,2015;88(2):220-230.
12 Khanna V,Armstrong PC,Warner TD,et al.Prostaglandin E1potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro:Insights using short thromboelastography.Platelets,2015;26(7):689-692.
13 West LE,Steiner T,Judge HM,et al.Vessel wall,not platelet,P2Y12 potentiates early atherogenesis.Cardiovasc Res,2014;102(3):429-435.
14 Lordkipanidze M,Pharand C,Schampaert E,et al.A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.Eur Heart J,2007;28(14):1702-1708.
15 Khaspekova SG,Ziuriaev IT,Iakushkin VV,et al.Mean platelet volume:interactions with platelet aggregation activity and glycoproteinⅡb-Ⅲa andⅠb expression levels.Biomed Khim,2014;60(1):94-108.
16 Momeni A,Filiaggi MJ.Degradation and hemostatic properties of polyphosphate coacervates.Acta Biomater,2016;41:328-341.
17 Matczak J,Nowak P.The role of polyphosphates in the blood coagulation process and the inflammation progress.Wiad Lek,2016;69(6):818-824.